Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2022 Earnings Conference Call March 3, 2023 8:30 AM ET

Company Participants

Jon Patton - Director, Investor Relations and Communications

Matt Coffey - Chief Executive Officer

Thomas Heineman - Chief Medical Officer

Andrew de Guttadauro - Global Head, Business Development

Kirk Look - Chief Financial Officer

Conference Call Participants

John Newman - Canaccord Genuity

Patrick Trucchio - H.C. Wainwright

Operator

Welcome to Oncolytics Biotech’s Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company’s request. I would now like to turn the call over to Jon Patton, Director of Investor Relations and Communications. Please go ahead.

Jon Patton

Thank you, operator and good morning everyone. Earlier this morning, Oncolytics issued a press release providing recent operational highlights and financial results for the fourth quarter and full year of 2022. A replay of today’s call will be available on the Events & Presentations section of the Oncolytics website approximately 2 hours after its completion. After remarks from company management, we will open the call for Q&A.

As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company’s business prospects and the development and commercialization of pelareorep, including statements regarding the company’s focus, strategy and objectives, company’s belief as to the potential and mode of action of pelareorep as a cancer therapeutic, the design, aims and anticipated benefits of the company’s current pending clinical trials, and anticipated timing of the release of additional data, the company’s plans and expectations regarding potential registrational studies, company’s business development plans and strategies, company’s financial runway, and other statements related to anticipated developments in the company’s business. These statements are based on management’s current expectations and beliefs and are subject to a number of factors, which involve known and unknown risks, delays uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or expectations implied by these forward-looking statements.

Any new forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that these statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, actions by regulatory agencies and those factors detailed in the company’s filings with the SEC. Oncolytics does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.